The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside

Jonathan J. Duplisea, Sharada Mokkapati, Devin Plote, Kimberly S. Schluns, David J. McConkey, Seppo Yla-Herttuala, Nigel R. Parker, Colin P. Dinney

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Background and Purpose: BCG unresponsive bladder cancer is an inherently resistant disease state for which the preferred treatment is radical cystectomy. To date, no effective intravesical therapies exist for patients who possess these resistant tumors. For this reason, many research groups are actively investigating/testing novel therapeutic agents to aid in bladder preservation for this patient population. This review article describes our 15-year experience developing and testing IFN-based gene therapy. Methods: A comprehensive review was performed of all studies pertaining to IFN-based gene therapy for non-muscle invasive bladder cancer from 2003 to 2018. Results and Conclusions: Over the past two decades, gene therapy has evolved into a powerful tool in our fight against cancer. After overcoming the initial barriers associated with gene delivery to the bladder, we have made significant strides forward in developing this novel therapeutic strategy for the treatment of this inherently resistant disease state. Our results to date are very encouraging; however, much work lies ahead to better understand and optimize this novel approach for treating non-muscle invasive bladder.

Original languageEnglish (US)
Pages (from-to)2041-2049
Number of pages9
JournalWorld journal of urology
Issue number10
StatePublished - Oct 1 2019


  • BCG unresponsive bladder cancer
  • Gene therapy
  • Instiladrin
  • Interferon-α

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside'. Together they form a unique fingerprint.

Cite this